Document 0077
 DOCN  M9460077
 TI    The impact of the syncytium-inducing phenotype of human immunodeficiency
       virus on disease progression.
 DT    9408
 AU    Richman DD; Bozzette SA; Department of Pathology, University of
       California, San Diego, La; Jolla 90293-0679.
 SO    J Infect Dis. 1994 May;169(5):968-74. Unique Identifier : AIDSLINE
       MED/94223101
 AB    Many patients infected with human immunodeficiency virus (HIV) yield
       syncytium-inducing (SI) virus isolates that are cytopathic in cell
       culture. The presence of SI virus was assessed in 325 persons entering
       11 antiretroviral therapy trials and correlated with both CD4 cell
       declines and clinical end points. Adjusted mean rates of CD4 cell count
       decline were 40 and 102 cells/year in the non-SI (NSI) and SI groups,
       respectively (P < .0001). Rates of decline in 16 persons converting from
       NSI to SI virus averaged 31 cells/year before conversion and 142
       cells/year afterward (P = .04). In a nested case-control analysis,
       persons who experienced surrogate marker end points or opportunistic
       infections were 2.3-3.5 times more likely to have SI virus than were
       controls (P = .01-.04) but who died were similar to controls with
       respect to virus phenotype (P = .70). Presence of the SI phenotype of
       HIV is a strong predictor of decline in CD4 cell count and progression
       of disease; however, controlling for the CD4 cell count, the SI
       phenotype did not increase the immediate risk of death.
 DE    Adult  Giant Cells/*MICROBIOLOGY  Human  HIV
       Infections/*MICROBIOLOGY/*PHYSIOPATHOLOGY  *HIV-1  Leukocyte Count
       Longitudinal Studies  Male  Phenotype  Regression Analysis  Support,
       Non-U.S. Gov't  Support, U.S. Gov't, Non-P.H.S.  Support, U.S. Gov't,
       P.H.S.  T4 Lymphocytes/PATHOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).